Relmada Therapeutics, Inc. (RLMD) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $6.28: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 5.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. (Note: Risk dimension 5.2/10 and A.R:R 5.3:1 are different metrics that happen to read the same number here.)
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with... Read more
Sell if holding. Engine safety override at $6.28: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 5.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. (Note: Risk dimension 5.2/10 and A.R:R 5.3:1 are different metrics that happen to read the same number here.) Chart setup: RSI 45 mid-range, Bollinger mid-band. Score 5.4/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-07-05Recent Developments — Relmada Therapeutics, Inc.
Latest news
- NEWS Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index — benzinga Jun 29, 2026 positive
Generated 2026-07-05T07:10:32Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $6.28: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 5.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. (Note: Risk dimension 5.2/10 and A.R:R 5.3:1 are different metrics that happen to read the same number here.) Chart setup: RSI 45 mid-range, Bollinger mid-band. Prior stop was $5.84. Score 5.4/10, moderate confidence.
Take-profit target: $11.02 (+75.5% upside). Prior stop was $5.84. Stop-loss: $5.84.
Quality below floor (1.6 < 4.0).
Relmada Therapeutics, Inc. trades at a P/E of N/A (forward -15.3). TrendMatrix value score: 9.4/10. Verdict: Sell.
11 analysts cover RLMD with a consensus score of 4.3/5. Average price target: $13.
What does Relmada Therapeutics, Inc. do?Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses...
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.